Volume 20 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(9): 1608-1611
WANG Xiao-ling, LI Xiao-hui, LIANG Hai, LI Miao-nan. Evaluation of drug-related problems in clinical application of rivaroxaban based on Granada-Ⅱ classification[J]. Chinese Journal of General Practice, 2022, 20(9): 1608-1611. doi: 10.16766/j.cnki.issn.1674-4152.002660
Citation: WANG Xiao-ling, LI Xiao-hui, LIANG Hai, LI Miao-nan. Evaluation of drug-related problems in clinical application of rivaroxaban based on Granada-Ⅱ classification[J]. Chinese Journal of General Practice, 2022, 20(9): 1608-1611. doi: 10.16766/j.cnki.issn.1674-4152.002660
shu

Evaluation of drug-related problems in clinical application of rivaroxaban based on Granada-Ⅱ classification

doi: 10.16766/j.cnki.issn.1674-4152.002660
  • 1.

    Department of Pharmacy, People's Hospital of Bozhou, Bozhou, Anhui 236800, China

Funds:

 KJ2018A0219

  • Received Date: 2022-02-18
    Available Online: 2022-11-29
    Abstract
  •   Objective  Based on the data analysis of inpatients using rivaroxaban, this study aimed to explore the drug-related problems (DRPs) of rivaroxaban in clinical application and to promote its rational use.  Methods  Through the hospital HIS system, 247 cases of rivaroxaban admitted to Bozhou People's Hospital from January 2020 to December 2021 were selected. The use of rivaroxaban, combination medication, and adverse reactions during hospitalisation of anticoagulant patients were retrospectively analysed using the international Spanish drug-related research method, the Granada-Ⅱ classification method. DRPs included necessity issues (DRP1, not getting the required drug treatment; DRP2, off-label use), safety issues (DRP3, wrong drug use; DRP4, low single dose of drug, less frequent administration, and insufficient course of treatment), effectiveness analysis issues (DRP5, contraindication drug use, bridging between anticoagulants, and adverse reactions; DRP6, overdose).  Results  A total of 247 cases of hospitalised patients receiving rivaroxaban were collected, and the total number of DRPs was 177, accounting for 71.66%. Rivaroxaban accumulated generating 204 DRPs, including 61 DRP2, 100 DRP4, 39 DRP5, and 4 DRP6.  Conclusion  The use of rivaroxaban in this hospital has the problems of no indication for use, unreasonable usage and dosage, and insufficient treatment. It needs to strengthen the intervention in DRPs of rivaroxaban to promote the reasonability of clinical application.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202121032.htm

    WANG Q Y, WU M F, LIU X, et al. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202121032.htm
    [2]
    马玉芬, 徐园, 王晓杰, 等. 普通外科患者静脉血栓栓塞症风险评估与预防护理专家共识[J]. 中华护理杂志, 2022, 57(4): 444-449. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHL202204009.htm

    马玉芬, 徐园, 王晓杰, et al. Expert consensus on risk assessment and prevention of venous thromboembolism in general surgical patients[J]. Chinese Journal of Nursing, 2022, 57(4): 444-449. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHL202204009.htm
    [3]
    林小娟, 黄小红, 黄涓涓, 等. 利伐沙班药物利用评价标准的建立与应用[J]. 中国现代应用药学, 2020, 37(20): 2543-2548. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYD202020020.htm

    LIN X J, HUANG X H, HUANG J J, et al. Establishment and application of drug use evaluation standard of rivaroxaban[J]. Chinese Journal of Modern Applied Pharmacy, 2020, 37(20): 2543-2548. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYD202020020.htm
    [4]
    林春忠, 赵亮, 王朝昕, 等. 基于数据挖掘的县级医院房颤患者抗凝治疗现状及影响因素研究[J]. 中华全科医学, 2021, 19(11): 1951-1955. doi: 10.16766/j.cnki.issn.1674-4152.002209

    LIN C Z, ZHAO L, WANG C X, et al. Current situation and influencing factors of anticoagulant therapy for patients with atrial fibrillation in county hospitals based on data mining[J]. Chinese Journal of General Practice, 2021, 19(11): 1951-1955. doi: 10.16766/j.cnki.issn.1674-4152.002209
    [5]
    任小婵, 罗选娟, 杨欢, 等. 新型口服抗凝药的临床应用研究进展[J]. 中华全科医学, 2018, 16(4): 615-619, 666. doi: 10.16766/j.cnki.issn.1674-4152.000171

    REN X C, LUO X J, YANG H, et al. New oral anticoagulants clinical application progress[J]. Chinese Journal of General Practice, 2018, 16(4): 615-619, 666. doi: 10.16766/j.cnki.issn.1674-4152.000171
    [6]
    宋佳伟, 陈慧娟, 施朕善, 等. 基于Granada-Ⅱ分类法评价临床应用注射用帕瑞昔布钠的药物相关问题[J]. 中国临床药学杂志, 2020, 29(6): 432-435. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZZ202006009.htm

    SONG J W, CHE H J, SHI Z S, et al. Evaluation of drug-related problems in clinical application of parecoxib sodium injection based on Granada-Ⅱ classification[J]. Chinese Journal of Clinical Pharmacy, 2020, 29(6): 432-435. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZZ202006009.htm
    [7]
    陈慧娟, 汪龙, 宋佳伟, 等. 基于Granada-Ⅱ分类法评价住院患儿质子泵抑制药临床使用中的药物相关问题[J]. 中国药师, 2020, 23(11): 2191-2194. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYSG202011023.htm

    CHEN H J, WANG L, SONG J W, et al. Evaluation of drug-related problems in clinical use of proton pump inhibitors in hospitalized children based on Granada-Ⅱ classification[J]. China Pharmacist, 2020, 23(11): 2191-2194. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYSG202011023.htm
    [8]
    汪龙, 程军, 朱玲娜, 等. 基于Granada-Ⅱ分类法评价红花注射液临床应用中存在的药物相关问题[J]. 中国新药与临床杂志, 2020, 39(1): 57-60. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202001020.htm

    WANG L, CHENG J, ZHU L N, et al. Evaluation of drug-related problems in clinical application of Honghua injection based on Granada-Ⅱ classification[J]. Chinese Journal of New Drugs and Clinical Remedies, 2020, 39(1): 57-60. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202001020.htm
    [9]
    MOHAN B P, ARAVAMUDAN V M, KHAN S R, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis[J]. Ann Gastroenterol, 2020, 33(5): 521-527.
    [10]
    赵岩, 杜书章, 李凌. 利伐沙班在冠心病合并肺栓塞患者中的抗栓作用研究[J]. 医药论坛杂志, 2019, 40(7): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX201907008.htm

    ZHAO Y, DU S Z, LI L. Application of rivaroxaban in patients with coronary heart disease complicated with pulmonary embolism[J]. Journal of Medical Forum, 2019, 40(7): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX201907008.htm
    [11]
    王瑶, 傅麒宁, 刘丽萍. 利伐沙班在深静脉血栓形成治疗中的应用进展[J]. 现代医药卫生, 2021, 37(10): 1683-1686. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202110020.htm

    WANG Y, FU Q N, LIU L P. Application of rivaroxaban in the treatment of deep vein thrombosis[J]. Journal of Modern Medicine & Health, 2021, 37(10): 1683-1686. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202110020.htm
    [12]
    中华医学会骨科学分会. 中国骨科大手术静脉血栓栓塞症预防指南[J]. 中华骨科杂志, 2016, 36(2): 65-71. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ202213001.htm

    Orthopaedics Society, Chinese Medical Association. Chinese Guidelines for the Prevention of venous thromboembolism in major orthopaedic Surgery[J]. Chinese Journal of Orthopaedics, 2016, 36(2): 65-71. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ202213001.htm
    [13]
    林庆荣, 杨明辉, 侯志勇. 中国创伤骨科患者围手术期静脉血栓栓塞症预防指南(2021)[J]. 中华创伤骨科杂志, 2021, 23(3): 185-192.

    LIN Q R, YANG M H, HOU Z Y. Guidelines for prevention of perioperative venous thromboembolism in Chinese orthopedic trauma patients (2021)[J]. Chinese Journal of Orthopaedic Trauma, 2021, 23(3): 185-192.
    [14]
    李辉, 姜格宁. 胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识(2018版)[J]. 中国肺癌杂志, 2018, 21(10): 739-752. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201810003.htm

    LI H, JIANG G N. Perioperative venous thromboembolism (VTE) prophalaxis in thoracic cancer patients: Chinese experts consensus[J]. Chinese Journal of Lung Cancer, 2018, 21(10): 739-752. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201810003.htm
    [15]
    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 中华消化杂志, 2020, 40(11): 721-730. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202012010.htm

    Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. Chinese Journal of Digestion, 2020, 40(11): 721-730. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202012010.htm
    [16]
    杜晓菲, 韦新焕, 仇丽霞, 等. 失代偿期肝硬化患者应用利伐沙班的安全性研究[J]. 北京医学, 2021, 43(7): 593-596. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX202107001.htm

    DU X F, WEI X H, QIU L X, et al. Safety of rivaroxaban in patients with decompensated cirrhosis[J]. Beijing Medical Journal, 2021, 43(7): 593-596. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX202107001.htm
    [17]
    张海洲, 李彩云, 杭永付, 等. 低剂量利伐沙班在冠心病患者抗栓治疗中出血风险的Meta分析[J]. 中国药学杂志, 2020, 55(24): 2063-2068. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX202024011.htm

    ZHANG H Z, LI C Y, HANG Y F, et al. Risk of bleeding in patients with coronary artery disease adding low dose rivaroxaban: A meta-analysis[J]. Chinese Pharmaceutical Journal, 2020, 55(24): 2063-2068. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX202024011.htm
    [18]
    张艳梅, 许邦龙, 王晓晨. 3种抗凝药物在心房颤动导管消融围术期的安全性比较[J]. 安徽医学, 2020, 41(4): 427-429. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202004020.htm

    ZHANG Y M, XU B L, WANG X C. Comparison of the safety of three anticoagulants during perioperative catheter ablation of atrial fibrillation[J]. Anhui Medical Journal, 2020, 41(4): 427-429. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202004020.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (277) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return